Genesis Therapeutics

Genesis Therapeutics

Pairing proven drug developers with the industry's most advanced small molecule discovery platform, to accelerate and optimize the development of new medicines.

Genesis Therapeutics is a company that is interested in providing artificial intelligence and bio-technologies in order to discover new medicines. The company was founded in 2019, in San Francisco, California, United States.

The company looks to combine novel deep neural networks, biophysical simulations, and computing infrastructures. The company has an artificial intelligence platform that expands the initial discovery of the PotentialNet and peer-reviewed methods for molecular property predictions. Their methods have been tested against current methods of chemistry.

Timeline

December 2020
Genesis Therapeutics raises a $52,000,000 series A round from T. Rowe Price, Rock Springs Capital, Andreessen Horowitz, Menlo Ventures and Radical Ventures.
November 21, 2019
Genesis Therapeutics raises a $4,100,000 seed round from Felicis Ventures, The a16z Cultural Leadership Fund and Andreessen Horowitz.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Genesis Therapeutics Series A round December 2020
52,000,000
December 2020
4 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Devin Coldewey
December 2, 2020
TechCrunch
Sifting through the trillions of molecules out there that might have powerful medicinal effects is a daunting task, but the solution biotech has found is to work smarter, not harder. Genesis Therapeutics has a new simulation approach and cross-disciplinary team that has clearly made an impression: the company just raised a $52 million A round. [...]

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.